Spurred on by Mod­er­na and Pfiz­er's suc­cess, a Bel­gian biotech has big am­bi­tions for its self-am­pli­fy­ing RNA vac­cine play

With the first wave of mR­NA-based Covid-19 vac­cines pro­vid­ing proof of con­cept to the en­tire field, in­vestors are see­ing dol­lar signs for plat­form plays once con­sid­ered moon­shots. Now, a Bel­gian biotech is get­ting in on the craze with a hefty ear­ly fundrais­ing haul for its own RNA plat­form.

Ziphius Vac­cines closed a $29.8 mil­lion Se­ries A, with a $6.13 mil­lion con­vert­ible loan to boot to de­vel­op its RNA plat­form, start­ing with Covid-19 and then mov­ing in­to oth­er in­fec­tious dis­eases, it said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER